CA-ENERGOUS
Today Energous Corporation (Nasdaq: WATT), the developer of WattUp®, a revolutionary wireless charging 2.0 technology, announced that it has received regulatory approval for its WattUp Near Field wireless charging technology in Japan.
“Having secured regulatory approval for our WattUp wireless charging technology in Japan is a major regulatory milestone for Energous,” said Stephen R. Rizzone, president and CEO of Energous Corporation. “This opens the door to sell WattUp-enabled products in a major Asia Pacific market.”
Energous’ WattUp wireless charging technology underwent testing by independent, accredited test labs and was determined to be compliant with all regulatory requirements in Japan.
“WattUp approval in Japan is a big step forward for Energous and our customers, while increasing momentum to achieve global market access,” said Dan Lawless, vice president of regulatory affairs at Energous Corporation. “We are establishing a regulatory framework for the large-scale deployment of wireless charging 2.0 through our substantial engagements in major international spectrum and standards organizations, combined with our direct work with governments around the world.”
“Currently wireless charging technologies – specifically non coil-based charging solutions – have not yet penetrated the Japan market, largely because Japan has historically proven to have a more rigid regulatory approval process. Energous Corporation is paving the way for the industry in the Japan market with the industry-first approval of its WattUp wireless charging technology. With this breakthrough, Energous continues to show progress in advancing its WattUp technology to meet the needs of partner and customer companies,” said Dinesh Kithany, lead industry analyst, wireless power and power supply at Omdia.
Some of the benefits of Energous’ WattUp technology for manufacturers include:
- A small footprint allowing WattUp to be integrated into products of various form factors, including small devices with curved edges or without flat surfaces
- Orientation freedom and 90-degree angle support
- Foreign object detection eliminating thermal issues with metal and other materials
- Interoperability with all WattUp-enabled products, even those from different manufacturers
To-date, Energous has secured regulatory approval for its WattUp wireless charging technology in the following countries:
Afghanistan |
Bermuda |
Curacao |
Germany |
Kosovo |
Netherlands |
Suriname |
Albania |
Bolivia |
Cyprus |
Ghana |
Latvia |
New Zealand |
Sweden |
Andorra |
Bosnia and Herzegovina |
Czech Republic |
Greece |
Liechtenstein |
Nicaragua |
Switzerland |
Angola |
Botswana |
Denmark |
Grenada |
Lithuania |
Norway |
Taiwan |
Antigua and Barbuda |
Brazil |
Djibouti |
Guatemala |
Luxembourg |
Panama |
Tajikistan |
Argentina |
Brunei |
Dominican Republic |
Guyana |
Macedonia |
Peru |
Tanzania |
Armenia |
Bulgaria |
Dominica |
Honduras |
Malawi |
Philippines |
Thailand |
Aruba |
Burkina Faso |
Ecuador |
Hungary |
Maldives |
Poland |
Trinidad and Tobago |
Australia |
Cambodia |
Egypt |
Iceland |
Malta |
Portugal |
Turkey |
Austria |
Canada |
El Salvador |
India |
Mexico |
Romania |
United Arab Emirates |
Azerbaijan |
Cayman Island |
Eritrea |
Indonesia |
Monaco |
Serbia |
Uganda |
Bahamas |
Central African Republic |
Estonia |
Ireland |
Mongolia |
Slovenia |
The United Kingdom |
Barbados |
Chile |
Ethiopia |
Italy |
Montenegro |
Solomon Island |
The United States |
Belarus |
Colombia |
Finland |
Jamaica |
Mozambique |
Slovakia |
Uruguay |
Belgium |
Costa Rica |
France |
Japan |
Myanmar (formerly Burma) |
South Africa |
Uzbekistan |
Belize |
Croatia |
Georgia |
Jordan |
Nepal |
Spain |
Venezuela |
Energous anticipates it will receive regulatory approval in additional markets later this year.
To learn more about Energous, please visit Energous.com or follow the company on Twitter , Facebook and LinkedIn .
About Energous Corporation
Energous Corporation (Nasdaq: WATT) is leading the next generation of wireless charging – wireless charging 2.0 – with its award-winning WattUp® technology, which supports fast, efficient contact-based charging, as well as charging at a distance. WattUp is a scalable, RF-based wireless charging technology that offers substantial improvements in contact-based charging efficiency, foreign object detection, orientation freedom and thermal performance compared to older, coil-based charging technologies. The technology can be designed into many different sized electronic devices for the home and office, as well as the medical, industrial, retail and automotive industries, and it ensures interoperability across products. Energous develops silicon-based wireless power transfer (WPT) technologies and customizable reference designs. These include innovative silicon chips, antennas and software, for a large variety of applications, such as smartphones, fitness trackers, hearables, medical sensors and more. Energous received the world’s first FCC Part 18 certification for at-a-distance wireless charging, and the company has 220 awarded patents for its WattUp wireless charging technology to-date. For more information, please visit Energous.com .
Safe Harbor Statement
This press release contains forward-looking statements that describe our future plans and expectations. These statements generally use terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or similar terms. Examples of our forward-looking statements in this release include our statements about technology developments, partner product development and wireless charging innovation. Our forward-looking statements speak only as of this date; they are based on current expectations and we undertake no duty to update them. Factors that could cause actual results to differ from what we expect include: uncertain timing of necessary regulatory approvals; timing of customer product development and market success of customer products; our dependence on distribution partners; and intense industry competition. We urge you to consider those factors, and the other risks and uncertainties described in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, in evaluating our forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005882/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
